Thao P Le, Eamon Conway, Edifofon Akpan, Isobel Abell, Patrick Abraham, Christopher M Baker, Patricia T Campbell, Deborah Cromer, Michael J Lydeamore, Yasmine McDonough, Ivo Mueller, Gerard Ryan, Camelia Walker, Yingying Wang, Natalie Carvalho, Jodie McVernon
{"title":"Cost-effective boosting allocations in the post-Omicron era of COVID-19 management","authors":"Thao P Le, Eamon Conway, Edifofon Akpan, Isobel Abell, Patrick Abraham, Christopher M Baker, Patricia T Campbell, Deborah Cromer, Michael J Lydeamore, Yasmine McDonough, Ivo Mueller, Gerard Ryan, Camelia Walker, Yingying Wang, Natalie Carvalho, Jodie McVernon","doi":"10.1101/2023.11.14.23298536","DOIUrl":null,"url":null,"abstract":"Background Following widespread exposure to Omicron variants, COVID-19 has transitioned to endemic cir-\nculation. Populations now have diverse infection and vaccination histories, resulting in heterogeneous\nimmune landscapes. Careful consideration of vaccination is required through the post-Omicron phase\nof COVID-19 management to minimise disease burden. We assess the impact and cost-effectiveness\nof targeted COVID-19 vaccination strategies to support global vaccination recommendations. Methods We integrated immunological, transmission, clinical and cost-effectiveness models, and simulated\npopulations with different characteristics and immune landscapes. We calculated the expected number\nof infections, hospitalisations and deaths for different vaccine scenarios. Costs (from a healthcare\nperspective) were estimated for exemplar country income level groupings in the Western Pacific\nRegion. Results are reported as incremental costs and disability-adjusted life years averted compared\nto no additional vaccination. Parameter and stochastic uncertainty were captured through scenario and\nsensitivity analysis. Findings Across different population demographics and income levels, we consistently found that annual\nelder-targeted boosting strategies are most likely to be cost-effective or cost-saving, while paediatric\nprograms are unlikely to be cost-effective. Results remained consistent while accounting for uncertain-\nties in the epidemiological and economic models. Half-yearly boosting may only be cost-effective in\nhigher income settings with older population demographics and higher cost-effectiveness thresholds. Interpretation These results demonstrate the value of continued booster vaccinations to protect against severe\nCOVID-19 disease outcomes across high and middle-income settings and show that the biggest health\ngains relative to vaccine costs are achieved by targeting older age-groups. Funding Funded by the World Health Organization.","PeriodicalId":501072,"journal":{"name":"medRxiv - Health Economics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Health Economics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2023.11.14.23298536","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background Following widespread exposure to Omicron variants, COVID-19 has transitioned to endemic cir-
culation. Populations now have diverse infection and vaccination histories, resulting in heterogeneous
immune landscapes. Careful consideration of vaccination is required through the post-Omicron phase
of COVID-19 management to minimise disease burden. We assess the impact and cost-effectiveness
of targeted COVID-19 vaccination strategies to support global vaccination recommendations. Methods We integrated immunological, transmission, clinical and cost-effectiveness models, and simulated
populations with different characteristics and immune landscapes. We calculated the expected number
of infections, hospitalisations and deaths for different vaccine scenarios. Costs (from a healthcare
perspective) were estimated for exemplar country income level groupings in the Western Pacific
Region. Results are reported as incremental costs and disability-adjusted life years averted compared
to no additional vaccination. Parameter and stochastic uncertainty were captured through scenario and
sensitivity analysis. Findings Across different population demographics and income levels, we consistently found that annual
elder-targeted boosting strategies are most likely to be cost-effective or cost-saving, while paediatric
programs are unlikely to be cost-effective. Results remained consistent while accounting for uncertain-
ties in the epidemiological and economic models. Half-yearly boosting may only be cost-effective in
higher income settings with older population demographics and higher cost-effectiveness thresholds. Interpretation These results demonstrate the value of continued booster vaccinations to protect against severe
COVID-19 disease outcomes across high and middle-income settings and show that the biggest health
gains relative to vaccine costs are achieved by targeting older age-groups. Funding Funded by the World Health Organization.